CRISPR: From Bacterial Defense System to Tool of the Future


When a bacterium was smarter than a scientist

Just after breakfast, sitting in his laboratory at the University of Alicante, Francisco Mojica stared at his computer screen in dismay. It was the 1990s, and he had just created a database of DNA sequences of extreme bacteria—organisms that lived in conditions that would kill almost any other life. These bacteria inhabited salt-saturated lakes—organisms adapted to be “salt lovers,” as their scientific name, halobalilia, implied.labiotech+1

But instead of the usual, orderly DNA sequences he expected, Mojica stumbled upon something strange: regularly repeated DNA fragments, separated by spaces with ever-changing sequences . They were like repeated words in a strange verse—”word-space-word-space-word.” Interesting. Almost like an archive. But an archive of what?wikipedia

Little did he know that he had just discovered one of the most groundbreaking technologies that would fundamentally revolutionize medicine, agriculture, and biology over the next two decades.

First Spark: The Strange Sequence from 1987

The history of CRISPR (acronym for Clustered Regularly Interspaced Short Palindromic Repeats) begins earlier, in Japan.bitesizebio

In 1987, while working on the gene encoding alkaline phosphatase in E. coli , Japanese scientist Yoshizumi Ishino and his team had an unexpected surprise. While cloning DNA for an experiment, they stumbled upon fragments of DNA that were repeated—a highly unusual finding. These sequences were organized into clusters and were regularly distributed along the bacterial genome.biocompare+1

Ishino and his team published their observations, but their significance was never fully explored. This discovery languished in the scientific literature, like a hidden treasure waiting for adventurers.biocompare

The Key to the Puzzle: Francisco Mojica Discovers the Function

Flash forward to the year 2000. Francisco Mojica, now a researcher at the University of Alicante, was working on a different question: how do bacteria from extreme environments adapt to changes in salt concentration? But his curiosity quickly veered elsewhere.labiotech

Using access to growing genetic databases, he began comparing these strange, repetitive sequences Ishino had previously discovered. Imagine his surprise when he discovered that the same repeats appeared in the genomes of bacteria studied around the world—in microorganisms from the ocean, soil, and caves .biocompare

In 2000, he and his colleagues published work showing that this cluster was highly evolutionarily conserved—and therefore must have meant something important. Its very preservation over millions of years of evolution indicated that nature does nothing without reason.biocompare

But that was just the beginning.

Eureka Moment: Virus in Bacterial DNA

A few years later, while comparing databases, Mojica noticed something extraordinary: DNA fragments nested between repeats in the bacterial genome were identical to fragments of the genomes of viruses (bacteriophages) that attack bacteria .labiotech

Not just any fragments – but fragments of actual viruses infectious to those same bacteria!

It was an immediately logical presumption: if a bacterium stores fragments of a virus’s DNA in its cell, it must have acquired this genetic material somehow . And if it holds them, it must need them for something.labiotech

Mojica hypothesized: CRISPR is a bacteria’s adaptive immune system . Once a virus attacks a bacterium and it becomes infected, part of the virus’s genome is squeezed into the CRISPR archive. The next time the same virus tries to attack that bacterium (or its descendants), the immune system will “remember” it and attack it.wikipedia+1

Sounds almost like memory? Because that’s exactly what it is— biological, genetic memory .

A path through the groves of scientific journals

In 2003, Mojica wrote a paper proposing this theory. He submitted it to Nature , one of the world’s most prestigious scientific journals. It was rejected. He tried the Proceedings of the National Academy of Sciences . It was rejected.wikipedia

Then Molecular Microbiology . Refusal.wikipedia

Nucleic Acids Research . Once again – refusal.wikipedia

He was frustrated, but he didn’t give up. The paper finally made it to the Journal of Molecular Evolution in February 2005. It wasn’t Nature, but it was a publication. Importantly, that same year, independently of Mojica’s work, another laboratory published similar findings.flagshippioneering+1

But something changed. Scientists began to listen.

Experimental Proof: Horvath and Siksnys Show It Works

Although Mojica proposed the hypothesis, experimental evidence came from a completely different direction – from laboratories that were studying… ferments for yogurt production.pmc.ncbi.nlm.nih

In 2005, Philippe Horvath’s team at Danisco (yes, the dairy giant!) investigated how Streptococcus thermophilus bacteria – used to produce yogurt and cheese – could be resistant to infectious viruses (bacteriophages).pmc.ncbi.nlm.nih

Horvath and his colleagues demonstrated experimentally what Mojica had proposed theoretically: when S. thermophilus was infected with a new bacteriophage, the bacterium integrated new sequences derived from the phage’s genome directly into its CRISPR region of DNA . Even better, the next time the same phage tried to infect descendants of that bacterium, they were resistant.pmc.ncbi.nlm.nih

This was not just a theory – it was experimental proof of a working biological immune system.pmc.ncbi.nlm.nih

Separately, that same year, Vytautas Siksnys from Lithuania published a paper showing that the CRISPR system from one bacterium ( S. thermophilus ) could be transferred to a completely different species— E. coli —and it would work there. This was important because it demonstrated the universality of the system.flagshippioneering

2006-2011: Developing the Foundation

In the following years, scientists around the world began to study CRISPR in more detail. Fiona Barrangou and others demonstrated exactly how CRISPR works—how bacteria “learn” to recognize viruses and use this knowledge to protect themselves.nature

Several variants of CRISPR systems have been discovered – CRISPR-Cas9 , CRISPR-Cas12a , and others. Each system had its own Cas proteins – enzymes that perform the actual “cutting” of DNA.pmc.ncbi.nlm.nih

It turned out that Cas9 , from Streptococcus pyogenes (the bacterium that causes angina), was particularly remarkable. When prompted by guide RNA, it would precisely cut DNA exactly where instructed.pmc.ncbi.nlm.nih

By 2011, scientists knew almost everything they needed to know about CRISPR in nature. But no one had yet considered: what if, instead of letting bacteria do what they do naturally, we scientists taught Cas9 to do what we wanted?

The San Juan Meeting and the History That Was Written

In 2011, at a scientific conference in San Juan, Puerto Rico, two scientists from different sides of the Atlantic met by chance.pmc.ncbi.nlm.nih

Jennifer Doudna , a protein structuralist at the University of California, Berkeley, specialized in studying biological mechanisms at the molecular level. Emmanuelle Charpentier , a microbiologist at Umeå University in Sweden, also studied bacterial immune systems.innovativegenomics+1

They talked about CRISPR. Doudna was fascinated; Charpentier was an expert. They decided to collaborate.pmc.ncbi.nlm.nih

2011: Charpentier Discovers the Third Missing Piece

Before Doudna and Charpentier deepened their collaboration, Charpentier had made a significant discovery in her Umeå lab. She was studying CRISPR with Streptococcus pyogenes and discovered something that would change everything.mpg

It turned out that in addition to krRNA (CRISPR RNA) and Cas9, there was a third, critically important component: tracrRNA (trans-activating crRNA) . This was a small but crucial RNA molecule.pmc.ncbi.nlm.nih+1

This was a groundbreaking observation because the tracrRNA turned out to be a “bridge”—it connected Cas9 to the krRNA in such a way that Cas9 knew where to look and where to cut.pmc.ncbi.nlm.nih

2012: The Turning Point When Nature Became a Tool

Now Doudna and Charpentier had all the pieces of the puzzle. In their UC Berkeley/Umeå lab, they worked together (communicating across the ocean) to assemble CRISPR-Cas9 into something that could be a controllable tool.embryo.asu

Their key contribution was elegant: instead of using two separate RNA molecules (krRNA and tracrRNA), they combined them into a single molecule , which they called single guide RNA (sgRNA) .embryo.asu

Why was this important? Because it simplified the technology. Instead of programming two different RNAs, scientists now had to program just one. It was like going from using a computer with two buttons to one with a single large button labeled with what you wanted to do.mpg+1

Experiment: Testing in Dish

In their experiment, Doudna, Charpentier and their team (including Martin Jinek and Michael Hauer from Berkeley, and Krzysztof Chylinski and Ines Fonfara from Umeå) set up a laboratory scene:embryo.asu

  1. They produced pure Cas9 protein – an enzyme not yet “programmed”embryo.asu
  2. They created guide RNA that could program Cas9 to search for a specific DNA sequence.embryo.asu
  3. They combined them in a laboratory tube – along with the target DNAembryo.asu

And they waited.

What happened: Cas9 precisely cut the DNA exactly where the guide RNA told it to . Not just anywhere—right there.embryo.asu

But that wasn’t the goal. Doudna and Charpentier were pursuing something much bigger: demonstrating that the CRISPR-Cas9 system can be programmed like a hyper-precise tool that scientists can target to ANY DNA sequence .embryo.asu

When Doudna and Charpentier showed they could program five different guide RNAs, each targeting a different site in the DNA, the idea was clear: It could work for any sequence a scientist wanted to edit .embryo.asu

Science Publication: The Moment When Everything Changed

Their manuscript reached the editorial office of Science in 2012.pmc.ncbi.nlm.nih

In the June 2013 issue of Science , an article was published: “RNA-guided genetic engineering of human pluripotent stem cells.” The title didn’t sound revolutionary, but its content was incredible.pmc.ncbi.nlm.nih

The article included a detailed description of the three CRISPR-Cas9 components:pmc.ncbi.nlm.nih

  • Cas9 protein (enzyme)
  • crRNA (lead part)
  • tracrRNA (connector)

And importantly , they showed how all three could work together as a programmed, precise DNA editing tool .pmc.ncbi.nlm.nih

But that was only part of it. Doudna and Charpentier proposed something radical: What if scientists could use this system not only in bacteria, but also in eukaryotic cells—like human cells?pmc.ncbi.nlm.nih

The scientific world reacted with madness.

The Year After: Feng Zhang and the First Editions in Mammalian Cells

In 2013, just a few months after Doudna-Charpentier’s publication, Feng Zhang of the MIT Broad Institute published his own paper in Science .embryo.asu

Zhang took the CRISPR-Cas9 described by Doudna and Charpentier and demonstrated that it could be delivered into living mouse and human cells and edit their genome .embryo.asu

It was a massively important demonstration. Theoretically, it worked in a tube. But would it work in living cells? Yes, and Zhang is proof.embryo.asu

Now scientists had not only a conceptual tool, but a practical tool.

Revolution: Six Months, Thousands of Articles

Six months after Doudna-Charpentier’s publication, dozens of labs around the world had already begun experimenting with CRISPR-Cas9.news.berkeley

Here’s why CRISPR was so transformative compared to previous technologies (such as ZFNs – Zinc Finger Nucleases, and TALENs – Transcription Activator-Like Effector Nucleases):ijisrt

aspectZFNLANGUAGESCRISPR-Cas9
Ease of designVery difficult, requires protein engineeringDifficult, but easier than ZFNVery easy – just change the RNA
Time to actWeeks/monthsDays/weeksHours/days
CostDearEasyVery cheap
PrecisionHighHighHigh
VersatilityLimited to certain sequencesMore universalUniversal
Multiplex (multiple targets at once)DifficultDifficultEasy

Scientists could now take any DNA sequence – from a human gene, mitochondrial DNA, bacteria, plants – and program Cas9 to cut it in hours.news.berkeley

It was like going from handwriting every letter of a document to having a golden pen that could write whatever you wanted.

First Triumphs: 2013-2015

By 2015, CRISPR-Cas9 had already been used to:

  • Gene editing in mouse cells – creating disease modelsaddgene
  • Mutation Repair – Scientists Worked on Serum Fibrosis and Beta-Thaliasiaaddgene
  • Gene function research – blocking genes to see what they doaddgene
  • Plant resistance formations – plants resistant to drought or diseaseaddgene

In 2015, Science named CRISPR its “Breakthrough of the Year” – the only laboratory tool to win this prestigious award.bitesizebio

Parallel History: The Battle for Patents

While Doudna and Charpentier published their results in Science , almost simultaneously, Zhang at MIT/Broad Institute was also working on the CRISPR project. The result: a patent controversy exists today.insights

Doudna and Charpentier filed their patent application in March 2013, but with priority from May 2012.insights

Zhang submitted his application in October 2013, but with priority from December 2012.insights

Zhang received the first patent – ​​the U.S. Patent and Trademark Office granted him Patent No. 8,697,359 in April 2015. But Doudna and Charpentier also hold patents (European and other).broadinstitute+1

In the world of medicine and business – where patents mean money – this battle continues to this day.

A Dramatic Turning: The Nobel Prize in 2020

In a year when the world was grappling with COVID-19, the Swedish Academy of Sciences awarded the 2020 Nobel Prize in Chemistry to exactly two women: Emmanuelle Charpentier and Jennifer Doudna “for developing a method for genome editing.”Nobel Prize

This was historic. It was the first time the Nobel Prize in Chemistry was awarded solely to two women . Charpentier and Doudna were pioneers not only in science but also in gender equality in science.pmc.ncbi.nlm.nih

During her Nobel speech, Doudna expressed her gratitude to Charpentier: “Without her commitment and vision, this would not have been possible.”

From 2013 to 2025: How Far We’ve Come

Fast forward to today. Since the first Science article in 2012, CRISPR has gone from a laboratory curiosity to a real-world tool in medicine:

  • 2019 : First CRISPR clinical trial in sickle cell patients in the USpmc.ncbi.nlm.nih
  • 2023 : FDA approves the first CRISPR-Cas9-based drug for sickle cell disease and thalassemia – Casgevypmc.ncbi.nlm.nih
  • 2024 : More than 1,500 CRISPR clinical trials worldwideinnovationhub
  • 2025 : CRISPR-edited cells are now being delivered to patients who say they “feel like new people”innovationhub

Summary: How Bacteria Taught Us to Heal

The story of CRISPR is a story of discovery that began with curiosity—why do bacteria have these strange DNA repeats?—and led to a medical revolution.

From Yoshizumi Ishino in 1987 discovering the mysterious sequences, to Francisco Mojica understanding their function, to Jennifer Doudna and Emmanuelle Charpentier seeing that the bacterial immune system could be a tool for humanity – each step has been extraordinary.mdpi+4

What bacteria have developed over millions of years of evolution—a self-defense system against viruses—has taught us how to treat human genetic diseases. Nature is our best engineer. We just had to pay attention.pmc.ncbi.nlm.nih+1

Today, in 2025, CRISPR is beyond the “can work” stage and entering the “actually works in patients” stage. This journey from infectious discovery to reliable medical tool took 38 years. But the wait was worth it.


Sources and References

– MDPI: CRISPR-Cas: Converting A Bacterial Defence Mechanism into A State-of-the-Art Genetic Manipulation Tool (2019)mdpi
– PMC/NIH: CRISPR-Cas9: From a bacterial immune system to genome-edited human cells in clinical trials (2017)pmc.ncbi.nlm.nih
– BioCompare: The History and Evolution of CRISPR (2021)biocompare
– Lab Biotechnology EU: Francis Mojica, the Spanish Scientist Who Discovered CRISPR (2022)labiotech
– Bitwise Bio: A Brief History of CRISPR-Cas9 Genome-Editing Tools (2024)bitesizebio
Wikipedia: Francisco Mojicawikipedia
– Innovative Genomics Institute: Jennifer Doudna and Emmanuelle Charpentier – Behind the Development of CRISPR (2025)innovativegenomics
– Flagship Pioneering: A History of CRISPR (2020)flagshippioneering
– PMC/NIH: Nobel Prize 2020 in Chemistry honors CRISPR (2020)pmc.ncbi.nlm.nih
– PMC/NIH: Breaker of chains (2021)pmc.ncbi.nlm.nih
– ASU Embryo Project: Jennifer Doudna and Emmanuelle Charpentier’s Experiment (2017)embryo.asu
– Broad Institute: Statements and background on CRISPR patent process (2025)broadinstitute
– CRISPR Therapeutics: Dr. Emmanuelle Charpentiercrisprtx
– Insights.bio: Revolutionizing genome editing with CRISPR/Cas9: patent dispute (2015)insights
– Max Planck Institute: Emmanuelle Charpentier: An artist in gene editing (2017)mpg
– Nobel Prize Official: Jennifer A. Doudna (2018)Nobel Prize
– PMC/NIH: The genome-editing decade (2021)pmc.ncbi.nlm.nih
– PMC/NIH: Blossom of CRISPR technologies and applications (2018)pmc.ncbi.nlm.nih
– International Journal of Innovation and Scientific Research: Comparative Review of ZFN, TALEN, and CRISPR/Cas9ijisrt
– UC Berkeley News: How CRISPR worksnews.berkeley
– AddGene: CRISPR History and Development for Genome Engineering (2024)addgene
– Innovation Hub: The Breakthrough of CRISPR (2023ub: The Breakthrough of CRISPR (2023)pmc.ncbi.nlm.nih

  1. https://www.labiotech.eu/interview/francis-mojica-crispr-interview/
  2. https://en.wikipedia.org/wiki/Francisco_Mojica
  3. https://bitesizebio.com/47927/history-crispr/
  4. https://www.biocompare.com/Editorial-Articles/578958-The-History-and-Evolution-of-CRISPR/
  5. https://www.flagshippioneering.com/timelines/a-history-of-crispr
  6. https://pmc.ncbi.nlm.nih.gov/articles/PMC8042634/
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC6199817/
  8. https://www.nature.com/articles/s41467-018-04252-2
  9. https://innovativegenomics.org/news/jennifer-doudna-emmanuelle-charpentier-development-crispr-genome-editing/
  10. https://crisprtx.com/about-us/leadership/dr-emmanuelle-charpentier
  11. https://www.mpg.de/10729312/emmanuelle-charpentier
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC7782372/
  13. https://embryo.asu.edu/pages/jennifer-doudna-and-emmanuelle-charpentiers-experiment-about-crisprcas-9-systems-role-adaptive
  14. https://news.berkeley.edu/2017/02/15/how-crispr-works-and-what-it-can-do/
  15. https://www.ijisrt.com/assets/upload/files/IJISRT25APR2221.pdf
  16. https://www.addgene.org/crispr/history/
  17. https://www.insights.bio/cell-and-gene-therapy-insights/journal/article/535/Revolutionizing-genome-editing-with-CRISPR-Cas9-patent-battles-and-human-embryos
  18. https://www.broadinstitute.org/crispr/journalists-statement-and-background-crispr-patent-process
  19. https://www.nobelprize.org/prizes/chemistry/2020/doudna/facts/
  20. https://pmc.ncbi.nlm.nih.gov/articles/PMC8571477/
  21. https://www.innovationhub.world/post/the-breakthrough-of-crispr
  22. https://www.mdpi.com/2079-6382/8/1/18/pdf
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC5470512/
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC4491743/
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC4084950/
  26. https://academic.oup.com/ismej/advance-article-pdf/doi/10.1093/ismejo/wrae108/58280201/wrae108.pdf
  27. https://pmc.ncbi.nlm.nih.gov/articles/PMC3883426/
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC5847661/
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC11285788/
  30. https://gna.it.com/crispr-discovery-history-pioneers
  31. https://breakthroughprize.org/Laureates/2/L63
  32. https://en.wikipedia.org/wiki/CRISPR
  33. https://www.bioagilytix.com/blog/origins-of-crispr-how-it-came-to-be/
  34. https://elifesciences.org/articles/73601
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC10541141/
  36. https://pmc.ncbi.nlm.nih.gov/articles/PMC5239572/
  37. https://pmc.ncbi.nlm.nih.gov/articles/PMC9377665/
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC5214730/
  39. https://pmc.ncbi.nlm.nih.gov/articles/PMC6014596/
  40. https://en.wikipedia.org/wiki/Feng_Zhang
  41. https://en.wikipedia.org/wiki/Emmanuelle_Charpentier
  42. https://pmc.ncbi.nlm.nih.gov/articles/PMC10454384/
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC10373057/
  44. https://pmc.ncbi.nlm.nih.gov/articles/PMC9589773/
  45. https://pmc.ncbi.nlm.nih.gov/articles/PMC6800964/
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC5319590/
  47. https://pmc.ncbi.nlm.nih.gov/articles/PMC4191047/
  48. https://www.sciencedirect.com/science/article/abs/pii/S0966842X16300683
  49. https://www.ptglab.com/news/blog/crispr-cas9-talens-and-zfns-the-battle-in-gene-editing/

迈向艾滋病治愈的最后一步——EBT-101蛋白

EBT-101:我们是否即将找到治愈艾滋病的方法?

自20世纪80年代初被发现以来,艾滋病毒(HIV,即人类免疫缺陷病毒)改变了现代医学,也改变了无数人的生活。如今,得益于抗逆转录病毒疗法(ART)的进步,艾滋病毒感染者可以拥有健康长寿的生活。然而,即使每日服药,病毒仍然潜伏在暗处,如同潜伏的猫一般,一旦我们停止服药,病毒就会伺机而动。

如果我们能彻底根除病毒,那会怎样?EBT-101 是一种新型基因编辑疗法,旨在治愈艾滋病,而不仅仅是控制它。听起来像科幻小说?科学家们正在进行相关测试。让我们深入了解一下这项可能带来医学革命的疗法。


为什么艾滋病如此难以治愈?

艾滋病毒非常隐蔽。它不仅在血液中循环,还会侵入免疫细胞的DNA,形成隐蔽的“病毒库”。只要你每天按时服药,病毒就会保持休眠状态。但只要停药片刻,艾滋病毒就会迅速复活。

这就是为什么很难找到真正治愈艾滋病的方法:这种病毒是你身体的一部分,隐藏着,就像电脑病毒埋在你的硬盘里一样。


EBT-101课程的独特之处是什么?

EBT-101 基于现代遗传学的神奇工具:CRISPR-Cas9。想象一下,一把超级精准的剪刀,可以定位并切割 HIV 病毒隐藏的特定 DNA 片段。

但EBT-101不仅仅关注CRISPR疗法!它最吸引人的地方在于:

  • 多重基因编辑:大多数基因编辑技术仅针对一个位点。EBT-101 则针对 HIV 可能藏匿于 DNA 中的三个位置。这就像一扇三重锁的门——配备三把钥匙,确保病毒无处遁形!
  • 长期效果  :动物研究表明,单次治疗即可消除足够多的病毒,使其永久失活。
  • AAV递送  :该工具通过一种无害的辅助病毒(称为腺相关病毒(AAV))导入体内,该病毒可将基因编辑指令直接发送到细胞。

临床试验是如何进行的?

第一步:安全第一

EBT-101 的 I 期临床试验于 2022 年启动,这意味着已有真实受试者参与了这项研究(https://www.clinicaltrials.gov/study/NCT05144386)。 在目前的早期临床阶段,主要问题包括:

  • 这种治疗方法安全吗?
  • 它会引起任何意想不到或危险的副作用吗?
  • 它会引起任何意想不到或危险的副作用吗?

谁可以参加?

第一项研究的对象是感染了 HIV-1 的成年人,他们在接受治疗多年后病毒载量仍然非常稳定。这一点至关重要,因为研究人员需要一个清晰、稳定的起点,才能确定 EBT-101 是否真的有效。

接下来会发生什么?

如果研究表明 EBT-101 是安全的(不会引起严重的副作用或“脱靶”基因改变),下一步将是尝试回答以下问题:

  • 人体清除体内隐藏的艾滋病毒的能力如何?
  • 停止服用抗艾滋病毒药物是否安全,不会导致病毒复发?
  • 这些效果能持续多久?

回答这些问题需要数年时间,还需要在更大规模的人群中进行进一步研究。一项科学突破将是发现某种疗法对少数人有效。


EBT-101面临的最大挑战是什么?

让我们坦诚面对现实——消除艾滋病并非易事!以下是我们面临的一些严峻挑战:

1. 彻底清除所有艾滋病毒储存库

HIV病毒潜伏在多种免疫系统细胞和各种组织中,例如深层淋巴结、肠道和大脑。治疗必须找到每一个受感染的细胞,才能阻止病毒再次传播。这种“大海捞针”般的难题是HIV研究中最棘手的挑战之一。

2. 避免副作用

CRISPR技术非常精准,但并非完美无缺。如果基因编辑剪刀出错——误剪了健康的人类DNA而非病毒本身——则可能导致严重的健康风险,例如癌症或其他疾病的发生。临床试验会对这些风险进行严密监控。

3. 机体的免疫反应

引入 CRISPR 工具和载体病毒(即使是像 AAV 这样无害的病毒)会引起人体防御机制的注意。如果免疫系统攻击载体系统,治疗效果可能会降低,甚至引发炎症。

4. 持久性:一次剂量是否足够?

早期研究带来了希望,但我们尚不清楚单一疗法是否能彻底根除艾滋病毒,或者病毒是否会在多年后复发。研究人员需要对参与者进行长期随访才能确定。

5. 可用性和成本

新型复杂基因疗法初期通常价格昂贵,可能仅限于富裕国家或资金雄厚的研究中心。确保所有艾滋病毒感染者都能获得EBT-101疗法,将是未来的一项重大挑战。

6. 伦理和监管方面的障碍

由于这项技术涉及编辑人类细胞的基因组,因此必须遵守严格的伦理规范并引发相关争论。在考虑广泛应用之前,必须充分了解其长期影响。


我们现在身处何方?未来又将面临什么?

世界各地的科学家都在密切关注EBT-101的试验结果。如果成功,不仅有望治愈艾滋病,还能为治愈其他由潜藏在我们DNA中的病毒引起的疾病铺平道路。各大公司和大学都在竞相改进基因编辑工具,以覆盖更多细胞,并使疗法更安全、更易于实施。

EBT-101 目前还不能治愈艾滋病,但治愈艾滋病(而不是控制艾滋病)的想法在我们有生之年可能会成为现实。


摘要:希望就在眼前

EBT-101是现代医学中最具突破性的理念之一。它利用CRISPR基因编辑技术,旨在从人类DNA中寻找并清除隐藏的HIV病毒,为真正持久治愈艾滋病带来希望。从实验室到患者床边,这条路漫长而艰辛,充满了科学难题和伦理挑战,但每一步都让我们离一个不再有艾滋病肆虐的世界更近一步。

艾滋病患者真的可以彻底翻过人生中的这一页吗?如果真是如此,EBT-101或许会作为一项真正的医学奇迹载入史册。

CRISPR–Cas9 protein

故事始于CRISPR-Cas9的发现。这项发现最初由艾曼纽·夏庞蒂埃(Emmanuelle Charpentier)发现并赞赏。在多年研究肺炎链球菌(Streptococcus pneumoniae)对抗抗生素的防御机制之后,她发现了一种RNA,这种RNA控制着一类在生命维持和自我防御过程中至关重要的分子的合成。她注意到某些细菌基因组中存在一段名为CRISPR的DNA序列,它作为抵御病毒防御系统的一部分发挥作用。通过复制入侵病毒的部分DNA并将其插入到这段DNA序列中,细菌能够在病毒再次入侵时识别它,并通过切割其DNA进行攻击。不同的CRISPR系统以不同的方式组织这种攻击;当时已知的所有系统都涉及一种名为CRISPR RNA的RNA分子。他们与约尔格·沃格尔(Jörg Vogel)合作,利用生物信息学方法发现,所使用的程序化RNA序列与基因组结果之间存在依赖关系。这揭示了该方法的三个主要组成部分:tracrRNA、CRISPR RNA 和 Cas9 蛋白。Cas9 蛋白最早由法国国家农业研究院 (INRA) 的 Lexander Bolotin 于 2005 年发现。但第一个发现 CRISPR 的科学家是……。此外,荷兰的 John van der Oost 也追踪到了 RNA 的编码部分 (crRNA),他当时使用的是大肠杆菌。下一个突破是在 2008 年由美国的 Marraffini 和 Sontheimer 取得的。他们证明,CRISPR 技术并非作为 RNA 抑制剂发挥作用,而是直接靶向 DNA。下一个发现再次属于 Emmanuelle Charpentier。她发现 tracrRNA 与 crRNA 形成双链,正是这种双链引导 Cas9 蛋白到达其靶点。2009 年夏天,她与 Elitza Deltcheva 合作,成功完成了 DNA 编辑实验。 2011年,立陶宛的Virginijus Siksnys取得了又一项进展。他的团队将CRISPR系统“移植”到不含II型CRISPR系统的细菌——大肠杆菌中。实验成功了——CRISPR单元被证明是自主的。他们还成功地进行了使用程序化crRNA片段的实验。但CRISPR的真正应用是由麻省理工学院博德研究所的张锋完成的,他已在人类和小鼠细胞中实现了靶向基因组擦除。

Source :

http://www.nature.comhttp://feldan.comhttps://www.broadinstitute.org